{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:31:00Z","timestamp":1782390660919,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12098-024-05337-1","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T04:25:28Z","timestamp":1732508728000},"page":"61-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Update on Cannabidiol in Drug-Resistant Epilepsy"],"prefix":"10.1007","volume":"92","author":[{"given":"Akanksha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-4691","authenticated-orcid":false,"given":"Priyanka","family":"Madaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"5337_CR1","first-page":"101035","volume":"51","author":"G Kumar","year":"2021","unstructured":"Kumar G. Evaluation and management of drug resistant epilepsy in children. Curr Probl Pediatr Adolesc Health Care. 2021;51:101035.","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"5337_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1007\/s12098-021-03668-x","volume":"88","author":"P Madaan","year":"2021","unstructured":"Madaan P, Gupta A, Gulati S. Pediatric Epilepsy surgery: indications and evaluation. Indian J Pediatr. 2021;88:1000\u20136.","journal-title":"Indian J Pediatr"},{"key":"5337_CR3","doi-asserted-by":"publisher","first-page":"106629","DOI":"10.1016\/j.eplepsyres.2021.106629","volume":"173","author":"S Bhanudeep","year":"2021","unstructured":"Bhanudeep S, Madaan P, Sankhyan N, et al. Long-term epilepsy control, motor function, cognition, sleep and quality of life in children with West syndrome. Epilepsy Res. 2021;173:106629.","journal-title":"Epilepsy Res"},{"key":"5337_CR4","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.lansea.2023.100170","volume":"12","author":"JK Sahu","year":"2023","unstructured":"Sahu JK, Madaan P, Prakash K. The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forward. Lancet Reg Health Southeast Asia. 2023;12:100170.","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"5337_CR5","doi-asserted-by":"publisher","first-page":"674483","DOI":"10.3389\/fneur.2021.674483","volume":"12","author":"A Fattorusso","year":"2021","unstructured":"Fattorusso A, Matricardi S, Mencaroni E, et al. The pharmacoresistant epilepsy: an overview on existent and new emerging therapies. Front Neurol. 2021;12:674483.","journal-title":"Front Neurol"},{"key":"5337_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamapediatrics.2022.5648","volume":"177","author":"N Devi","year":"2023","unstructured":"Devi N, Madaan P, Kandoth N, Bansal D, Sahu JK. Efficacy and safety of dietary therapies for childhood drug-resistant epilepsy: a systematic review and network meta-analysis. JAMA Pediatr. 2023;177:258\u201366.","journal-title":"JAMA Pediatr"},{"key":"5337_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791\u2013804.","journal-title":"Drugs"},{"key":"5337_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.seizure.2022.04.004","volume":"99","author":"N Devi","year":"2022","unstructured":"Devi N, Madaan P, Ameen R, Sahu JK, Bansal D. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: a network meta-analysis. Seizure. 2022;99:164\u201375.","journal-title":"Seizure"},{"key":"5337_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.seizure.2021.06.020","volume":"91","author":"N Devi","year":"2021","unstructured":"Devi N, Madaan P, Asrar MM, Sahu JK, Bansal D. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: an indirect treatment comparison. Seizure. 2021;91:316\u201324.","journal-title":"Seizure"},{"key":"5337_CR10","unstructured":"US Food and Drug Administration. Label EPIDIOLEX (cannabidiol) oral solution. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"},{"key":"5337_CR11","unstructured":"CDSCO SEC Recommendations, SEC (Neurology & Psychiatry) meeting 15.02.2023; 2023. Available at: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Neurology%20amp;%20Psychiatry%20%2015.02.2023%20%20.pdf"},{"key":"5337_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","volume":"227","author":"SA Bonini","year":"2018","unstructured":"Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300\u201315.","journal-title":"J Ethnopharmacol"},{"key":"5337_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","volume":"96","author":"D Samanta","year":"2019","unstructured":"Samanta D, Cannabidiol. A review of clinical efficacy and safety in epilepsy. Pediatr Neurol. 2019;96:24\u20139.","journal-title":"Pediatr Neurol"},{"key":"5337_CR14","unstructured":"Drug Factsheet marijuana\/cannabis. Available at: https:\/\/www.dea.gov\/sites\/default\/files\/2020-06\/Marijuana-Cannabis-2020_0.pdf"},{"key":"5337_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","volume":"22","author":"RA Gray","year":"2020","unstructured":"Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in Epilepsy. Epileptic Disord. 2020;22:10\u20135.","journal-title":"Epileptic Disord"},{"key":"5337_CR16","doi-asserted-by":"publisher","first-page":"611278","DOI":"10.3389\/fnbeh.2020.611278","volume":"14","author":"C Mart\u00ednez-Aguirre","year":"2020","unstructured":"Mart\u00ednez-Aguirre C, Carmona-Cruz F, Velasco AL, et al. Cannabidiol acts at 5-HT(1A) receptors in the human brain: relevance for treating temporal lobe epilepsy. Front Behav Neurosci. 2020;14:611278.","journal-title":"Front Behav Neurosci"},{"key":"5337_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586\u201392.","journal-title":"Epilepsia"},{"key":"5337_CR18","unstructured":"Meissner H, Cascella M. Cannabidiol (CBD) [Updated 2024 May 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556048\/"},{"key":"5337_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","volume":"34","author":"E Ben-Menachem","year":"2020","unstructured":"Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. CNS Drugs. 2020;34:661\u201372.","journal-title":"CNS Drugs"},{"key":"5337_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ebcr.2017.10.001","volume":"9","author":"L Grayson","year":"2018","unstructured":"Grayson L, Vines B, Nichol K, Szaflarski JP. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2018;9:10\u20131.","journal-title":"Epilepsy Behav Case Rep"},{"key":"5337_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8:989.","journal-title":"J Clin Med"},{"key":"5337_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88:730\u20136.","journal-title":"Life Sci"},{"key":"5337_CR23","doi-asserted-by":"publisher","unstructured":"Ye H, Wan Y, Wang X et al. Cannabidiol protects against neurotoxic reactive astrocytes-induced neuronal death in mouse models of epilepsy. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-3878760\/v1","DOI":"10.21203\/rs.3.rs-3878760\/v1"},{"key":"5337_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/can.2023.0067","volume":"9","author":"M Masoumi","year":"2024","unstructured":"Masoumi M, Manavi MA, Mohammad Jafari R, et al. Cannabidiol anticonvulsant effects against lithium-pilocarpine-induced status epilepticus in male rats are mediated by neuroinflammation modulation and cannabinoids 1 (CB1), but not CB2 and GABA(A) receptors. Cannabis Cannabinoid Res. 2024;9:797\u2013808.","journal-title":"Cannabis Cannabinoid Res"},{"key":"5337_CR25","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ejn.16350","volume":"59","author":"X Li","year":"2024","unstructured":"Li X, Yennawar M, Wiest A, et al. Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5(R59X) knock-in mice. Eur J Neurosci. 2024;59:3337\u201352.","journal-title":"Eur J Neurosci"},{"key":"5337_CR26","doi-asserted-by":"publisher","first-page":"106635","DOI":"10.1016\/j.yebeh.2019.106635","volume":"102","author":"R de Carvalho Reis","year":"2020","unstructured":"de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis. Epilepsy Behav. 2020;102:106635.","journal-title":"Epilepsy Behav"},{"key":"5337_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1590\/1806-9282.2022d689","volume":"68","author":"A Silvinato","year":"2022","unstructured":"Silvinato A, Floriano I, Bernardo WM. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Rev Assoc Med Bras. 2022;68:1345\u201357.","journal-title":"Rev Assoc Med Bras"},{"key":"5337_CR28","doi-asserted-by":"publisher","first-page":"114238","DOI":"10.1016\/j.expneurol.2022.114238","volume":"359","author":"A Talwar","year":"2023","unstructured":"Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. Exp Neurol. 2023;359:114238.","journal-title":"Exp Neurol"},{"key":"5337_CR29","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/epi.17000","volume":"62","author":"AD Patel","year":"2021","unstructured":"Patel AD, Mazurkiewicz-Be\u0142dzi\u0144ska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62:2228\u201339.","journal-title":"Epilepsia"},{"key":"5337_CR30","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/epi.17036","volume":"62","author":"IE Scheffer","year":"2021","unstructured":"Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62:2505\u201317.","journal-title":"Epilepsia"},{"key":"5337_CR31","doi-asserted-by":"publisher","first-page":"109210","DOI":"10.1016\/j.yebeh.2023.109210","volume":"144","author":"S Kochen","year":"2023","unstructured":"Kochen S, Villanueva M, Bayarres L, Daza-Restrepo A, Gonzalez Martinez S, Oddo S. Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy. Epilepsy Behav. 2023;144:109210.","journal-title":"Epilepsy Behav"},{"key":"5337_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085\u201396.","journal-title":"Lancet"},{"key":"5337_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/dmcn.15072","volume":"64","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang J, Wang C. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Dev Med Child Neurol. 2022;64:305\u201313.","journal-title":"Dev Med Child Neurol"},{"key":"5337_CR34","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320.","journal-title":"N Engl J Med"},{"key":"5337_CR35","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s40265-023-01936-y","volume":"83","author":"S Lattanzi","year":"2023","unstructured":"Lattanzi S, Trinka E, Russo E, et al. Pharmacotherapy for Dravet syndrome: a systematic review and network meta-analysis of randomized controlled trials. Drugs. 2023;83:1409\u201324.","journal-title":"Drugs"},{"key":"5337_CR36","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617\u201324.","journal-title":"Epilepsia"},{"key":"5337_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78:285\u201392.","journal-title":"JAMA Neurol"},{"key":"5337_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","volume":"60","author":"O Devinsky","year":"2019","unstructured":"Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60:294\u2013302.","journal-title":"Epilepsia"},{"key":"5337_CR39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. New Engl J Med. 2018;378:1888\u201397.","journal-title":"New Engl J Med"},{"key":"5337_CR40","first-page":"485","volume":"25","author":"R Abu-Sawwa","year":"2020","unstructured":"Abu-Sawwa R, Scutt B, Park Y. Emerging use of epidiolex (cannabidiol) in epilepsy. J Pediatr Pharmacol Ther. 2020;25:485\u201399.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"5337_CR41","unstructured":"FDA Regulation of Cannabis and Cannabis-Derived Products. Including Cannabidiol (CBD). Available at: https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd. Accessed on August 08, 2024."},{"key":"5337_CR42","unstructured":"API (Active Pharmaceutical Ingredients.) Medical Grade C-B-D. Available at: https:\/\/www.indiamart.com\/proddetail\/api-active-pharmaceutical-ingredients-medical-grade-c-b-d-2850364964355.html. Accessed on July 20, 2024."},{"key":"5337_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12956","author":"RT Wechsler","year":"2024","unstructured":"Wechsler RT, Burdette DE, Gidal BE, et al. Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Epilepsia Open. 2024. https:\/\/doi.org\/10.1002\/epi4.12956","journal-title":"Epilepsia Open"},{"key":"5337_CR44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1474-4422(20)30060-0","volume":"19","author":"A Lamb","year":"2020","unstructured":"Lamb A, Dawoud D, Dent R, Elliott N, Adler AI. Cannabidiol with clobazam for seizures associated with dravet and Lennox-Gastaut syndromes. Lancet Neurol. 2020;19:290\u20131.","journal-title":"Lancet Neurol"},{"key":"5337_CR45","doi-asserted-by":"publisher","first-page":"106936","DOI":"10.1016\/j.eplepsyres.2022.106936","volume":"183","author":"R Benini","year":"2022","unstructured":"Benini R, Asir N, Yasin A, et al. Landscape of childhood epilepsies - a multi-ethnic population-based study. Epilepsy Res. 2022;183:106936.","journal-title":"Epilepsy Res"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-024-05337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-024-05337-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-024-05337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T03:38:49Z","timestamp":1733888329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-024-05337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["5337"],"URL":"https:\/\/doi.org\/10.1007\/s12098-024-05337-1","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}